Partners:





Dennis F. Willson, J.D.
H. Perry Fell, Ph.D., M.B.A.
Glenn Kawasaki, Ph.D., J.D., M.B.A.
Omar K. Haffar, Ph.D.




Glenn Kawasaki, MBA, JD, Ph.D. (ITI Board Chair), President, Catch Incorporated. Dr. Kawasaki is a founder of International Therapeutics. He has a Ph.D. in genetics, an M.B.A., and a law degree each from the University of Washington. He was the first scientist and the chair of the Science Board at ZymoGenetics, Inc. Dr. Kawasaki was the founder, CEO, president, and research director at Aptein, Inc. At Aptein, Dr. Kawasaki pioneered a technology known as "ribosome display," which is being used to engineer antibodies and other polypeptides. This biotech firm merged into Cambridge Antibody Technology (CAT) in 1998.

In 1999 he founded Catch Incorporated, an ongoing Seattle diagnostics firm to measure homocysteine levels in human blood. Dr. Kawasaki remains an executive officer and a consultant of Catch Inc., which is based on his scientific input. Dr. Kawasaki also serves as a Director of Sound Pharmaceuticals Incorporated.

Dennis F. Willson, J.D., President & CEO, Cytokine PharmaSciences, Inc. (CPSI). Mr. Willson is a founder of CPSI, a private biotechnology company in King of Prussia (Philadelphia area), Pennsylvania. CPSI licensed its anti-viral technology to International Therapeutics for founders' stock, a Board position, and revenue sharing from products dependent upon this technology. Mr. Willson began his career as an attorney in the pharmaceutical industry as Regional Counsel, Latin America, for Abbott Laboratories. While at Abbott he moved from the practice of law to the business side, training sales representatives and product managers at Abbott's affiliate in Argentina. In 1985 he joined Rorer Group where, after a series of promotions, he became Managing Director of that company's Spanish operations in 1987. Following Rorer's merger with Rhone-Poulenc, Mr. Willson worked for a brief time at Carrington Laboratories in Dallas. In 1992, he left Carrington to co-found CPSI with Richard Storm, who was the former President of Rorer International. Mr. Willson received his J.D. from the University of California, Hastings College of Law in 1976 and his B.A. from Notre Dame in 1973. He is fluent in Spanish and Italian and knows Portuguese and French.

H. Perry Fell, Ph.D., M.B.A. Chairman, Chief Strategy Officer, Seattle Genetics, Bothell, WA. Prior to co-founding Seattle Genetics, Dr. Fell was with the Bristol-Myers Squibb Pharmaceutical Research Institute (1986-1997) and directed the Molecular Immunology Department from 1989-1997. Dr. Fell received an M.B.A. from the University of Washington, a Ph.D. in Immunology from the University of Texas Health Science Center at Dallas, Southwestern Medical School, and a B.S. in Microbiology from the University of Texas at Arlington. Dr. Fell has authored 30 scientific papers and holds 6 patents.

Omar Haffar, Ph.D., President and Chief Science Officer, International Therapeutics, Inc. see Executive Officers.